Atea Pharmaceuticals Reports $42M Net Loss in Q3 2025, Increases R&D Spending

Atea Pharmaceuticals, Inc. reported a net loss of $42.0 million for the third quarter of 2025, compared to a loss of $31.2 million in the same period last year. The company's total operating expenses increased to $45.6 million from $37.2 million year-over-year, primarily driven by a significant rise in research and development costs, which surged to $38.3 million from $26.2 million. This increase reflects heightened spending on the Phase 3 clinical development program for its lead product candidate, a regimen of bemnifosbuvir and ruzasvir for hepatitis C virus (HCV) treatment. General and administrative expenses decreased to $7.2 million from $11.0 million, largely due to lower stock-based compensation.

For the nine months ending September 30, 2025, Atea's total operating expenses were $126.0 million, down from $153.9 million in the prior year. The reduction was attributed to decreased research and development expenses, which fell to $100.2 million from $118.4 million, as the company completed its COVID-19 Phase 3 SUNRISE-3 clinical trial in 2024. Interest income also declined, totaling $13.1 million for the nine-month period, compared to $19.8 million in 2024, reflecting lower investment balances.

As of September 30, 2025, Atea held $329.3 million in cash, cash equivalents, and marketable securities, a decrease from $454.7 million at the end of 2024. The company has not generated any product revenue since its inception and does not anticipate doing so until it secures regulatory approval for its product candidates. Atea's liquidity is expected to support its operations through at least 2027, allowing it to continue its clinical programs and manage operational costs.

Strategically, Atea has made significant moves, including the initiation of patient enrollment in its Phase 3 clinical trials for HCV in April and June 2025. The company also completed a share repurchase program, buying back 3.1 million shares for approximately $11.4 million during the third quarter. Additionally, Atea has entered into a license agreement with Merck for the development and commercialization of ruzasvir, which includes milestone payments tied to the progress of its clinical trials.

Looking ahead, Atea remains focused on advancing its HCV treatment regimen through clinical development and preparing for potential commercialization. The company is also exploring additional product candidates for other viral infections, including hepatitis E. However, Atea acknowledges the challenges of securing adequate funding and the risks associated with clinical trials, which could impact its operational plans and financial condition.